These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 25782332

  • 1. Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
    Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.
    Trop Med Int Health; 2015 Jul; 20(7):914-8. PubMed ID: 25782332
    [Abstract] [Full Text] [Related]

  • 2. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 3. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M, Staszewski S, Doerr HW.
    Antivir Ther; 2007 Oct 06; 12(5):695-703. PubMed ID: 17713153
    [Abstract] [Full Text] [Related]

  • 4. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, Study 934 Team.
    J Acquir Immune Defic Syndr; 2009 Oct 01; 52(2):209-21. PubMed ID: 19644384
    [Abstract] [Full Text] [Related]

  • 5. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
    J Acquir Immune Defic Syndr; 2006 Dec 15; 43(5):535-40. PubMed ID: 17057609
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R, Herrera L, Moreno S.
    Clin Ther; 2008 Feb 15; 30(2):372-81. PubMed ID: 18343275
    [Abstract] [Full Text] [Related]

  • 7. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.
    PLoS One; 2013 Feb 15; 8(5):e64459. PubMed ID: 23691224
    [Abstract] [Full Text] [Related]

  • 8. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH, Okomo Assoumou MC, Jacobs GB, Yekwa EL, Lyonga E, Mesembe M, Eyoh A, Ikomey GM.
    BMC Infect Dis; 2019 Feb 26; 19(1):194. PubMed ID: 30808298
    [Abstract] [Full Text] [Related]

  • 9. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, Furrer H, Brinkman K, Sabin CA, Reiss P, Mallon PW, PREPARE (Preventing Progression of Adipose Tissue Redistribution) Investigators.
    J Clin Endocrinol Metab; 2013 Apr 26; 98(4):1659-66. PubMed ID: 23436922
    [Abstract] [Full Text] [Related]

  • 10. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
    McGee KC, Shahmanesh M, Boothby M, Nightingale P, Gathercole LL, Tripathi G, Harte AL, Shojaee-Moradie F, Umpleby AM, Das S, Al-Daghri NM, McTernan PG, Tomlinson JW.
    Antivir Ther; 2012 Apr 26; 17(3):495-507. PubMed ID: 22300946
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
    Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, Schuttner L, Mulenga LB, Bolton-Moore C, Chintu NT, Sheneberger R, Stringer EM, Stringer JS.
    J Acquir Immune Defic Syndr; 2011 Dec 15; 58(5):475-81. PubMed ID: 21857354
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
    Arrizabalaga J, Arazo P, Aguirrebengoa K, García-Palomo D, Chocarro A, Labarga P, Muñoz-Sánchez MJ, Echevarría S, Oteo JA, Uriz J, Letona S, Fariñas MC, Peralta G, Pinilla J, Ferrer P, Alvarez ML, Iribarren JA.
    HIV Clin Trials; 2007 Dec 15; 8(5):328-36. PubMed ID: 17956834
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.